Project Grant R43AG082625

Award Date 9/1/23
Completion Date 8/31/24
Dollars Obligated $1.1M
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Madison, WI 53711, USA
Similar Awards
This Project Grant award of $2,683,965 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will support the development and optimization of an improved all-human cellular system, or "brain-chip", for studying Alzheimer's disease and related dementias (ADRDs). The key objectives are to: 1) define delivery conditions for introducing patient blood cells and plasma into...
This $614,424 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to better understand the role of microglia, the brain's immune cells, in the development of Alzheimer's disease (AD). The University of Washington (UW) will leverage novel explainable AI techniques and human induced pluripotent stem cell (iPSC) models to uncover subtle microglial changes that occur early in AD progression. Specifically, UW will expose microglia-neuron iPSC cultures to...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
This Project Grant award of $3,317,325.00 from the National Institutes of Health's Trans-NIH Research Support program (CFDA 93.310) will support research to investigate the role of immune dysregulation and nerve growth factor (NGF) dysfunction in the development of Alzheimer's disease (AD) in individuals with Down syndrome (DS). The key objectives are to: 1) elucidate the relationships between immune deregulation, NGF dysmetabolism, and AD hallmarks in DS brain tissue and cell cultures; 2)...
This $500,000 Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) will support Sxrna Technologies, Inc. in developing an organoid toolkit for Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD). The company aims to create a platform for identifying senescent cells in living tissue, which can provide insights into the aging process and enable high-throughput drug screening in complex 3D tissue models. Specifically, the grant will fund...
The National Institute on Aging awarded a $1,931,965 Project Grant (CFDA 93.866 - Aging Research) to the Regenerative Research Foundation, a non-profit organization in Albany, New York. The purpose of this federal grant is to develop and validate a novel human induced pluripotent stem cell (iPSC) model that incorporates cerebral cortical neurons, glia, vascular endothelial cells, and microglia to study cerebrovascular interactions in Alzheimer's disease-related dementias (ADRD). The R61 phase of...
This $500,000 Project Grant was awarded on September 15, 2024 by the National Institute on Aging (CFDA 93.866 Aging Research program) to Neucyte Inc., a minority-owned small business specializing in advanced biomedical research and development. The funding will support the development of a miniaturized "mini-brain" microphysiological system (MPS) platform using Alzheimer's disease (AD) patient-derived cells. The goal is to create a scalable, reproducible in vitro brain model that can...
The National Institute on Aging (NIA) awarded a $619,681 Project Grant (CFDA 93.866 - Aging Research) to The Leland Stanford Junior University (Stanford University) to develop innovative tools for studying the complex genetic interactions underlying Alzheimer's disease (AD) pathogenesis. The project, titled "Combinatorial Perturbation with Multi-Omics Readout to Dissect Etiology of Alzheimer's Disease Using Stem Cell and In Vivo Models", will create a toolkit combining gene-editing...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,883 to Degrome Therapeutics, Inc. to develop small-molecule degraders of the amyloid precursor protein (APP) as novel therapeutics for Alzheimer's disease (AD). The project aims to optimize lead APP degrader compounds to improve their potency, solubility, and blood-brain barrier permeability, with the goal of identifying the most promising candidates for further development and evaluation...
This Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $3,845,311 to the University of California, San Diego (UCSD) to investigate the early determinants of Alzheimer's disease (AD) using age-equivalent neurons derived from mild cognitive impairment (MCI) patients. The project aims to better understand the convergence of risk factors, including polygenic variants and biological aging, on molecular pathways that initiate and...

HUMAN NEURAL ORGANOID MODELING OF ALZHEIMER'S DISEASE NEUROINFLAMMATION FOR DRUG DISCOVERY - PROJECT SUMMARY/ABSTRACT ALZHEIMER'S DISEASE (AD) IS THE MOST PREVALENT NEURODEGENERATIVE DISEASE WITH MORE THAN 6.5 MILLION AMERICANS CURRENTLY LIVING WITH AD DEMENTIA. AD IS DEFINED BY ITS NEUROPATHOLOGICAL HALLMARKS WHICH INCLUDE ASS PEPTIDE PLAQUE DEPOSITS, INTRANEURONAL TAU TANGLES AND NEURONAL LOSS. A MAJOR COMPONENT OF THE AD PROCESS IS NEUROINFLAMMATION. GENOME-WIDE ASSOCIATION STUDIES (GWAS) HAVE REVEALED SEVERAL IMMUNE GENES WHICH ARE RISK FACTORS FOR DEVELOPING LATE-ONSET AD. SEVERAL OF THESE AD RISK GENES SUCH AS SPI1 AND TREM2 ARE HIGHLY EXPRESSED IN MICROGLIA, THE BRAIN'S RESIDENT MACROPHAGE-LIKE POPULATION. MICROGLIA PHAGOCYTOSE ASS AND PLAY A CENTRAL ROLE IN THE BRAIN'S RESPONSE TO AMYLOID PLAQUES AND THE NEURODEGENERATIVE PROCESS. WHILE PLURIPOTENT STEM CELL-DERIVED NEURAL ORGANOIDS DO NOT TYPICALLY CONTAIN IMMUNE CELL POPULATIONS, STEM PHARM'S HYDROGEL-ENABLED NEURAL ORGANOIDS ALLOW FOR INCORPORATION OF MICROGLIA IN A REPRODUCIBLE, 96-WELL PLATE FORMAT AMENABLE TO SCREENING APPLICATIONS. USING THIS TECHNOLOGY, OUR PRELIMINARY DATA DEMONSTRATE MICROGLIA INCORPORATE INTO THE NEURAL ORGANOIDS AND RESPOND APPROPRIATELY TO INFLAMMATORY STIMULI INCLUDING ASS OLIGOMERS AND APOPTOTIC NEURONS. WORK IN THIS PROPOSAL WILL LEAD TO THE GENERATION OF A HUMAN AD-NEUROINFLAMMATION ORGANOID MODEL BY EXPOSING CULTURES WITH OLIGOMERIC ASS AND APOPTOTIC NEURONAL CELLS TO INDUCE AD-LIKE NEUROINFLAMMATORY RESPONSES, ULTIMATELY ENABLING A MORE BIOLOGICALLY RELEVANT HUMAN AD MODEL FOR DRUG DISCOVERY APPLICATIONS FOCUSED ON IMMUNE MODULATION. SPECIFIC AIMS WILL 1) OPTIMIZE THE MODEL AND ESTABLISH THE GENE EXPRESSION SIGNATURE OF THE MICROGLIA; 2) AND INCORPORATE MICROGLIA ENGINEERED WITH MUTATIONS IN THE AD ASSOCIATED GENE TREM2. COMPLETION OF THESE SPECIFIC AIMS WILL ESTABLISH A FLEXIBLE NEUROINFLAMMATION MODEL SYSTEM CAPABLE OF SCREENING THE EFFECTS OF COMPOUNDS OR INCORPORATING MICROGLIA HARBORING MUTANT AD-ASSOCIATED GENES. PHASE II STUDIES WILL SEEK TO EXPAND THE CAPABILITIES OF THE MODEL BY ESTABLISHING AND OPTIMIZING READOUTS TO MEASURE THE EFFECT OF INFLAMMATION ON THE NEURONAL CELL POPULATIONS AND ESTABLISH ORGANOIDS FROM ADDITIONAL DONORS. ULTIMATELY, THIS WORK WILL DEVELOP COMMERCIALLY AVAILABLE, NOVEL MODELS OF THE AD INFLAMMATION PROCESS WHICH CAN SERVE TO SUPPLEMENT THE MANY RODENT MODEL SYSTEMS CURRENTLY AVAILABLE.

Posted 8/21/23, 12:00 AM